Long-Term Immunogenicity and Efficacy of a 9-valent Conjugate Pneumococcal Vaccine in Human Immuno-deficient Virus Infected and Non-infected Children in the Absence of a Booster Dose of Vaccine
The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4–92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI −7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of ≥0.2 μg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age. This article was published in the journal Vaccine.
Author: Madhi S
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Madhi S. Long-term Immunogenicity and Efficacy of a 9-valent Conjugate Pneumococcal Vaccine in Human Immuno-deficient Virus Infected and Non-infected Children in the Absence of a Booster Dose of Vaccine. Vaccine. 2007;25(13):2451-2457.
Resource types: Peer-reviewed journal